To validate the suitability of MPLA-tDCs for autologous immunotherapy of autoimmune disorders, it is crucial to confirm their ability to act at different levels of an immune response, either by directing differentiation of naive CD4+ T cells with certain antigen-specificity toward a regulatory profile or by reprograming autoreactive memory CD4+ T cells. The gene discussed is CD4; the disease is Autoimmunity.